Case Studies · Amandeep Singh, Ph.D. ·

Start-up strategy support - NASH diagnostics AI platform

Helped a newly formed company shape their product development and go-to-market strategy, secured a key partnership with a top Australian university KOL, and provided fundraising strategy and pitching coaching.

Client Industry: AI Diagnostics / Multi-OMICs / Healthcare
Key Areas: Business strategy, Partnership development, Fundraising

Objective

A newly formed AI platform company specializing in NASH (Non-Alcoholic Steatohepatitis) diagnostics through multi-OMICs and EHR data integration engaged us to establish foundational business strategy and accelerate market entry. The founders needed comprehensive support across product development strategy, market positioning, and investor readiness.

Our Approach

  • Strategy development: Collaborated with the founder to refine the product development roadmap and craft a compelling go-to-market strategy tailored to the competitive NASH diagnostics landscape. Identified key market entry points and validated commercial viability through systematic market analysis.

  • Partnership Development:
    Sourced and facilitated a strategic partnership with a leading Key Opinion Leader (KOL) at a top-tier Australian university, establishing critical clinical validation pathways and enhancing the platform's scientific credibility for regulatory and commercial success.

  • Fundraising & Pitch Optimization:
    Developed a comprehensive fundraising strategy aligned with the company's development milestones and market opportunity. Provided hands-on coaching to the founder on investor pitching, focusing on articulating the unique value proposition of multi-OMICs integration and the significant unmet need in NASH diagnostics.

Impact

  • Established a clear product development and commercialization roadmap with defined market entry strategy

  • Secured a high-value academic partnership that strengthened clinical validation capabilities and market positioning

  • Equipped the founder with investor-ready materials and refined pitching skills to effectively communicate the platform's differentiated approach to NASH diagnostics

 

Subscribe to The BioStrat Brief on LinkedIn